Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01807520 · ClinicalTrials.gov registry record · Phase 3
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 198
- Enrollment target
NCT01807520 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 198 participants.
The verdict
NCT01807520, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 198 participants
- Enrollment target
Study Summary
This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2013-06-20 |
| Est. Completion | 2017-01-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01807520
The ClinicalTrials.gov registry entry for NCT01807520 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01807520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01807520 about?
NCT01807520 is a clinical study titled "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis". This purpose of this study was to demonstrate the efficacy of secukinumab versus placebo on nail psoriasis and to assess long-term efficacy, safety and tolerability of secukinumab.
What is the current status of trial NCT01807520?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 198 participants. The study started on 2013-06-20. Estimated completion is 2017-01-03.
What interventions are being tested in trial NCT01807520?
The interventions under investigation include: Placebo (BIOLOGICAL), Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01807520?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.